CEBP Infection and Cancer: Biology, Therapeutics, and Prevention 2008 Conference on Cancer Prevention - Washington, D.C.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alberts, D. S.
Right arrow Articles by Batta, A. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alberts, D. S.
Right arrow Articles by Batta, A. K.
Cancer Epidemiology Biomarkers & Prevention Vol. 12, 197-200, March 2003
© 2003 American Association for Cancer Research

Fecal Bile Acid Concentrations in a Subpopulation of the Wheat Bran Fiber Colon Polyp Trial1

David S. Alberts2, Janine G. Einspahr, David L. Earnest, Mary F. Krutzsch, Po Lin, Lisa M. Hess, David K. Heddens, Denise J. Roe, Maria Elena Martínez, Gerald Salen and A. K. Batta

Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724-5024 [D. S. A., J. G. E., M. F. K., P. L., L. M. H., D. J. R., M. E. M.]; Novartis Pharmaceuticals, East Hanover, New Jersey 07936-1080 [D. L. E.]; Eastern Arizona College, Globe, Arizona 85552 [D. K. H.]; and The University of Medicine and Dentistry of New Jersey, Newark, New Jersey 07018-1095 [G. S., A. K. B.]

Factors that affect the concentration of secondary bile acids in the aqueous phase of stool may have a greater impact on colon carcinogenesis than those that only modify the total fecal bile acid concentration. This hypothesis was tested using stool samples of a subset of participants enrolled in a Phase III colorectal adenomatous polyp prevention trial, which documented the inability of a 13.5 g/day wheat bran fiber (WBF) supplement to reduce polyp recurrence.

Stool was collected from 68 consecutively consented participants who were enrolled in a Phase III clinical trial of WBF for the prevention of adenomatous polyp recurrence. Nineteen (27.9%) of these fecal bile acid substudy participants were on the low fiber (2.0 g/day) intervention group, whereas 49 (72.7%) were on the high fiber (13.5 g/day) intervention group for ~3 years. Sixty-four participants had both the aqueous and solid phases of stool samples analyzed for bile acid content. Bile acid concentrations, measured in µg/ml for fecal water and µg/mg for dry feces, were determined for lithochilic, deoxycholic, chenodeoxycholic, cholic, ursodeoxycholic, isodeoxycholic, isoursodeoxycholic, ursocholic, 7-ketolithocholic, and 12-ketolithocholic acids.

There were no significant differences between the low and high fiber groups concerning mean or median aqueous phase concentrations of lithocholic or deoxycholic bile acids. In contrast, the median concentrations of deoxycholic acid and other secondary bile acids (including lithochilic, isodeoxycholic, ursodeoxycholic, isoursodeoxycholic, ursocholic, 7-ketolithocholic, and 12-ketolithocholic acids) were significantly lower for the high fiber group in the solid-phase stool (P < 0.05).

These results document that a high WBF intervention, taken for a median of 2.4 years, does not significantly reduce aqueous-phase concentrations of secondary bile acids in stool, although their concentrations in solid-phase stool were suppressed. Thus, the inability of the high WBF intervention to reduce colorectal adenoma recurrence may be a consequence of its lack of effect on fecal aqueous-phase secondary bile acid concentrations.




This article has been cited by other articles:


Home page
JNCI J Natl Cancer InstHome page
D. S. Alberts, M. E. Martinez, L. M. Hess, J. G. Einspahr, S. B. Green, A. K. Bhattacharyya, J. Guillen, M. Krutzsch, A. K. Batta, G. Salen, et al.
Phase III Trial of Ursodeoxycholic Acid To Prevent Colorectal Adenoma Recurrence
J Natl Cancer Inst, June 1, 2005; 97(11): 846 - 853.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.